Scilex Holding Company focuses on acquiring, developing, and commercializing non-opioid pain management products for the treatment of acute and chronic pain. Its commercial products include ZTlido (lidocaine topical system) 1.8% (ZTlido), a prescription lidocaine topical product for the relief of neuropathic pain associated with postherpetic neuralgia (PHN), which is a form of post-shingles nerve pain; ELYXYB, a ready-to-use oral solution …
Full SCLXW analysis →
Competitive advantage assessment
Key strengths
ROIC Sustainably Above PeersROIC at 100.0th percentile exceeds peers and WACC, demonstrating superior capital allocation.
Key risks
Commodity Pressure / Weak DifferentiationGross margin at 27.8th percentile with high volatility suggests weak pricing power or commoditized products.
Scilex Holding Company ranks #18 of 20
scored companies in Drug Manufacturers - General by moat score — the top 90%.
The widest moat in the group is Novo Nordisk A/S (NVO)
at 74/100.
Moat scores for companies ranked near SCLXW in Drug Manufacturers - General
How SCLXW scores on the Corporate Default defenses
Pricing Power
Score 10
· 20% of the moat score
Pricing power is the ability to raise prices without losing volume.
Cost Advantage
Score 11
· 15% of the moat score
A cost advantage means delivering the same product for structurally less — better purchasing, denser distribution, a more automated process.
Customer Stickiness
Score 23
· 15% of the moat score
Stickiness is what makes revenue repeat without being re-won every year.
Capital Efficiency
Score 68
· 18% of the moat score
Capital efficiency asks what the company earns on the money tied up in the business.
Resilience
Score 20
· 17% of the moat score
Resilience is the capacity to get through a bad year on its own terms — enough liquidity, enough interest cover, and enough cash generation to avoid a rescue financing or a forced sale.
Scale & Market Position
Score 15
· 15% of the moat score
Scale matters only when it converts into economics.
Scilex Holding Company (SCLXW) scores 26 out of 100 on the StatsAlpha Moat Map, which rates its competitive advantage as developing. It ranks #18 of 20 scored companies in Drug Manufacturers - General, the top 90%. The score is a weighted composite of 6 competitive defenses, each measured against industry peers of 19 companies in Drug Manufacturers - General. Its strongest defense is Capital Efficiency (68/100) and its weakest is Pricing Power (10/100).
How does Scilex Holding Company compare with other Drug Manufacturers - General companies?
Scilex Holding Company ranks #18 of 20 scored companies in Drug Manufacturers - General by moat score. The widest moat in Drug Manufacturers - General is Novo Nordisk A/S (NVO) at 74/100. The companies ranked closest are Scilex Holding Company (SCLX) at 27 just above it and Amarin Corporation plc (AMRN) at 23 just below it.
How is the moat score calculated?
Each company is scored with an industry-specific template — Corporate Default in this case, chosen because the defenses that matter to a bank are not the ones that matter to a software company. Every defense combines several financial signals, and each signal is measured as a percentile against a peer group of 19 companies in Drug Manufacturers - General. The defenses are then weighted to produce the overall score out of 100.
Why is Scilex Holding Company scored with the Corporate Default template?
Most public companies sell a product or a service at a margin, so the moat question is whether that margin survives contact with competitors. The Corporate template scores the six defenses that show up in a general operating company's financial signature: whether it can hold price, produce more cheaply than rivals, keep its customers, earn a return above its cost of capital, withstand a downturn, and turn size into economics.
Which competitive defenses are measured for Scilex Holding Company?
The Corporate Default template measures 6 defenses, and SCLXW scores: Pricing Power (10), Cost Advantage (11), Customer Stickiness (23), Capital Efficiency (68), Resilience (20), Scale & Market Position (15). Each is scored independently as a percentile against peers, so a company can be strong on one and weak on another — the overall score reflects how those defenses are weighted for this industry.
We value your privacy
We use cookies to enhance your browsing experience, analyze site traffic, and personalize content. By clicking 'Accept All', you consent to our use of cookies.
Read our cookie policy
Cookie Preferences
Manage your cookie preferences. Essential cookies are always enabled.